Dyne Therapeutics 

Yahoo Finance • 2 days ago

Dyne cut to Perform at Oppenheimer on valuation

[Wall Street New York stock exchange stock market] alexsl Shares of Dyne Therapeutics (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]) fell on Friday after Oppenheimer downgraded the neuromuscular disease company to Perform from Outperf... Full story

Yahoo Finance • 5 days ago

Dyne Therapeutics rises on positive data from myotonic dystrophy trial

[Ribonucleic acid strands consisting of nucleotides - 3d illustration] Christoph Burgstedt/iStock via Getty Images * Dyne Therapeutics (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]) shares rose after one-year results from its ongoin... Full story

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Decline Pre-Bell Tuesday

Health care stocks were declining pre-bell Tuesday, with the Health Care Select Sector SPDR Fund (XL PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden report... Full story

Yahoo Finance • 7 days ago

Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best stocks to buy under $20. On September 29, Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare/MHLW granted Orphan Drug designation for its investigational t... Full story

Yahoo Finance • 9 days ago

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 13 days ago

Dyne: Ministry Of Health In Japan Grants Orphan Drug Designation For DYNE-251

(RTTNews) - Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that... Full story

Yahoo Finance • 13 days ago

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, I... Full story

Yahoo Finance • 23 days ago

DYN Crosses Above Key Moving Average Level

In trading on Thursday, shares of Dyne Therapeutics Inc (Symbol: DYN) crossed above their 200 day moving average of $13.82, changing hands as high as $13.98 per share. Dyne Therapeutics Inc shares are currently trading up about 5.9% on th... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock jumped 4.1% after Raymond James analyst Martin Auster upgraded the company from Outperform to Strong Buy and raised the price target to $35.00 from $31.00. The upgrade reflects inc... Full story

Yahoo Finance • 2 months ago

Stocks Turn Mixed on Strength in the Magnificent Seven Megacaps

The S&P 500 Index ($SPX) (SPY) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.03%.  September E-mini S&P futures (ESU25) are down -0.13%, and Sep... Full story

Yahoo Finance • 2 months ago

Stocks Pressured by Rising Bond Yields

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futu... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN).  Such investors are advised to contact Danielle Peyton at newac... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences stock soars on Novartis takeover approach report

Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical giant Novartis (NYSE:NVS) has approached the rare disease-focused biotech company about a potential t... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics stock rises after FDA grants breakthrough therapy status

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock rose 3.6% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its DYNE-251 treatment for Duchenne muscular... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeut... Full story

Yahoo Finance • 2 months ago

Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials?

(RTTNews) - Dyne Therapeutics Inc. (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, is advancing its programs in Myotonic Dystrophy and Duchenne Muscular Dystrophy, aiming for potential c... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics extends cash runway as it advances key drug programs

Investing.com -- Dyne Therapeutics, Inc. (NASDAQ:DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its neuromuscular disease therapies toward potential... Full story